Target type: biologicalprocess
Any process that regulates translation occurring at the postsynapse. [PMID:20427644]
Postsynaptic translation is a critical process for the formation and maintenance of neuronal connections, known as synapses. These connections are essential for learning and memory formation, and their strength is modulated by the translation of specific mRNAs. Here's a detailed description of the regulation of translation at the postsynapse:
**1. Localized mRNA Transport and Anchoring:**
* mRNAs encoding proteins involved in synaptic plasticity are often transported to the postsynapse, where they become localized.
* These mRNAs are often bound to RNA-binding proteins, such as FMRP, which helps in their transport and stabilization.
**2. Synaptic Activity and Signaling Cascades:**
* Stimulation of the synapse triggers the release of neurotransmitters that activate downstream signaling pathways.
* These pathways include the MAPK (mitogen-activated protein kinase) pathway, the PI3K (phosphoinositide 3-kinase) pathway, and the CaMKII (calcium/calmodulin-dependent protein kinase II) pathway.
**3. Initiation Factor Regulation:**
* Signaling pathways activate protein kinases that can phosphorylate eukaryotic initiation factors (eIFs), such as eIF4E, eIF4G, and eIF2.
* Phosphorylation of these factors can promote or inhibit translation initiation, depending on the specific factor and its phosphorylation site.
* For example, phosphorylation of eIF4E by mTOR (mammalian target of rapamycin) promotes translation initiation.
**4. MicroRNA Regulation:**
* MicroRNAs (miRNAs) are small non-coding RNAs that can regulate gene expression at the post-transcriptional level.
* miRNAs can bind to the 3' UTR (untranslated region) of target mRNAs and repress their translation.
* Synaptic activity can influence the expression and activity of specific miRNAs, thereby controlling the translation of target mRNAs.
**5. Ribosome Biogenesis and Trafficking:**
* Translation at the synapse requires ribosomes, which are the protein synthesis machinery.
* Synaptic activity can regulate the synthesis and transport of ribosomal subunits to the postsynapse.
* This ensures that sufficient ribosomes are available for local protein synthesis.
**6. Stress Granule Formation:**
* Under stress conditions, such as during neuronal activity, ribosomes can form aggregates called stress granules.
* These granules can sequester mRNAs and translation factors, preventing translation initiation.
* Stress granule formation is thought to be a protective mechanism that prevents the synthesis of unnecessary proteins during stress.
**7. Specific mRNA Regulation:**
* Individual mRNAs can be specifically regulated at the postsynaptic level.
* For example, the mRNA encoding BDNF (brain-derived neurotrophic factor) is specifically localized to the postsynapse and its translation is regulated by synaptic activity.
* This precise control ensures that the appropriate proteins are synthesized at the correct time and location.
**8. Translation in Dendritic Spines:**
* Dendritic spines are small protrusions on dendrites that receive synaptic inputs.
* Local translation within dendritic spines is essential for synaptic plasticity, as it allows for the rapid synthesis of proteins involved in synapse formation and function.
* These proteins can modify the structure and function of the synapse, contributing to learning and memory formation.
**9. Translation in the Axon:**
* While not strictly postsynaptic, regulation of translation also occurs in axons, playing a crucial role in axon growth and maintenance.
* This process often involves local regulation of mRNAs encoding proteins involved in axon guidance and transport.
In summary, the regulation of translation at the postsynapse is a complex and highly controlled process. It involves a sophisticated interplay of signaling pathways, RNA-binding proteins, microRNAs, and ribosomes, ultimately leading to the synthesis of specific proteins that contribute to the formation and maintenance of neuronal connections. This precise regulation ensures that synapses are appropriately modified in response to neuronal activity, enabling processes such as learning and memory formation.'
"
Protein | Definition | Taxonomy |
---|---|---|
Eukaryotic elongation factor 2 kinase | An elongation factor 2 kinase that is encoded in the genome of human. [PRO:DNx, UniProtKB:O00418] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
rottlerin | rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis. rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1); | aromatic ketone; benzenetriol; chromenol; enone; methyl ketone | anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite |
nh 125 | NH 125: structure in first source | ||
a-484954 | A-484954: eEF2K inhibitor; structure in first source | ||
entrectinib | entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours. entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source | benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide | antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
nms p937 | NMS P937: a polo-like kinase 1 inhibitor; structure in first source | ||
nms-p118 | NMS-P118: a PARP-1 inhibitor; structure in first source | ||
nms-e973 | NMS-E973: structure in first source |